Cancer incidence and mortality in patients with type 2 diabetes treated with human insulin: A cohort study in Shanghai

Journal article


Gu, Yunjuan, Wang, Chunfang, Zheng, Ying, Hou, Xuhong, Mo, Yifei, Yu, Weihui, Zhang, Lei, Hu, Cheng, Nan, Hairong, Chen, Lei, Li, Jie, Liu, Yuxiang, Huang, Zhezhou, Han, Ming, Bao, Yuqian, Zhong, Weijian and Jia, Weiping. (2013) Cancer incidence and mortality in patients with type 2 diabetes treated with human insulin: A cohort study in Shanghai. PLoS ONE. 8(1), pp. 1 - 9. https://doi.org/10.1371/journal.pone.0053411
AuthorsGu, Yunjuan, Wang, Chunfang, Zheng, Ying, Hou, Xuhong, Mo, Yifei, Yu, Weihui, Zhang, Lei, Hu, Cheng, Nan, Hairong, Chen, Lei, Li, Jie, Liu, Yuxiang, Huang, Zhezhou, Han, Ming, Bao, Yuqian, Zhong, Weijian and Jia, Weiping
Abstract

Aim The aim was to investigate the association between human insulin and cancer incidence and mortality in Chinese patients with type 2 diabetes. Methods We recruited 8,774 insulin-naïve diabetes patients from the Shanghai Diabetes Registry (SDR). The follow-up rate was 85.4%. All subjects were divided into the insulin use cohort (n = 3,639) and the non-insulin use cohort (n = 5,135). The primary outcome was the first diagnosis of any cancer. The secondary outcome was all-cause mortality. Cox proportional hazards model was used to estimate the relative risk (RR) of cancer and mortality. Results We observed 98 cancer events in the insulin use cohort and 170 in the non-insulin use cohort. Cancer incidence rates were 78.6 and 74.3 per 10,000 patients per year in the insulin users and the non-insulin users, respectively. No significant difference in cancer risk was observed between the two cohorts (adjusted RR = 1.20, 95% CI 0.89–1.62, P = 0.228). Regarding site-specific cancers, only the risk of liver cancer was significantly higher in the insulin users compared to that in the non-insulin users (adjusted RR = 2.84, 95% CI 1.12–7.17, P = 0.028). The risks of overall mortality (adjusted RR = 1.89, 95% CI 1.47–2.43, P<0.0001) and death from cancer (adjusted RR = 2.16, 95% CI 1.39–3.35, P = 0.001) were all significantly higher in the insulin users than in the non-insulin users. Conclusion There was no excess risk of overall cancer in patients with type 2 diabetes who were treated with human insulin. However, a significantly higher risk of liver cancer was found in these patients. Moreover, insulin users showed higher risks of overall and cancer mortality. Considering that individuals treated with insulin were more likely to be advanced diabetic patients, caution should be used in interpreting these results.

Year2013
JournalPLoS ONE
Journal citation8 (1), pp. 1 - 9
PublisherPublic Library of Science
ISSN1932-6203
Digital Object Identifier (DOI)https://doi.org/10.1371/journal.pone.0053411
Scopus EID2-s2.0-84872144498
Open accessOpen access
Page range1 - 9
Research GroupMary MacKillop Institute for Health Research
Publisher's version
Place of publicationUnited States
Permalink -

https://acuresearchbank.acu.edu.au/item/88983/cancer-incidence-and-mortality-in-patients-with-type-2-diabetes-treated-with-human-insulin-a-cohort-study-in-shanghai

  • 0
    total views
  • 6
    total downloads
  • 0
    views this month
  • 0
    downloads this month
These values are for the period from 19th October 2020, when this repository was created.

Export as

Related outputs

Malignant and benign phenotypes of multimorbidity in heart failure: Implications for clinical practice
Chen, Lei, Chan, Yih-Kai, Busija, Lucy, Norekval, Tone M., Riegel, Barbara and Stewart, Simon. (2019) Malignant and benign phenotypes of multimorbidity in heart failure: Implications for clinical practice. Journal of Cardiovascular Nursing. 34(3), pp. 258 - 266. https://doi.org/10.1097/JCN.0000000000000557
Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin largine once-daily plus thrice-daily prandial insulin lispro) therapy in East Asian patients with type 2 diabetes
Jia, Weiping, Xiao, Xinhua, Ji, Qiuhe, Ahn, Kyu-Jeung, Chuang, Lee-Ming, Bao, Yuqian, Pang, Can, Chen, Lei, Gao, Fei, Tu, Yinfang, Li, Pengfei and Yang, Jun. (2015) Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin largine once-daily plus thrice-daily prandial insulin lispro) therapy in East Asian patients with type 2 diabetes. The Lancet Diabetes & Endocrinology. 3(4), pp. 254 - 262. https://doi.org/10.1016/S2213-8587(15)00041-8
The worldwide epidemiology of type 2 diabetes mellitus - Present and future perspectives
Chen, Lei, Magliano, Dianna J. and Zimmet, Paul Z.. (2012) The worldwide epidemiology of type 2 diabetes mellitus - Present and future perspectives. Nature Reviews Endocrinology. 8(4), pp. 228 - 236. https://doi.org/10.1038/nrendo.2011.183
Screening for diabetes
Backholer, K., Chen, Lei and Shaw, Jonathan E.. (2012) Screening for diabetes. Pathology. 44(2), pp. 110 - 114. https://doi.org/10.1097/PAT.0b013e32834e8e12
Explaining the increase of diabetes prevalence and plasma glucose in mauritius
Magliano, Dianna J., Söderberg, Stefan, Zimmet, Paul Z., Chen, Lei, Joonas, Noorjehan, Kowlessur, Sudhir, Larhubarbe, Jose, Gaoneadry, Dhanunjaye, Pauvaday, Vassen, Tuomilehto, Jaakko, Alberti, K. George M. M. and Shaw, Jonathan E.. (2012) Explaining the increase of diabetes prevalence and plasma glucose in mauritius. Diabetes Care. 35(2), pp. 87 - 91. https://doi.org/10.2337/dc11-0886
Maximizing efficiency and cost-effectiveness of Type 2 diabetes screening: The AusDiab study
Chen, Lei, Magliano, Dianna J., Balkau, Beverley, Wolfe, R., Brown, L., Tonkin, A. M., Zimmet, Paul Z. and Shaw, J. E.. (2011) Maximizing efficiency and cost-effectiveness of Type 2 diabetes screening: The AusDiab study. Diabetic Medicine. 289(4), pp. 414 - 423. https://doi.org/10.1111/j.1464-5491.2010.03188.x